Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Assessment of MRD in AML

Francesco Buccisano • 18 Sep 2020
SOHO Italy 2020
Leukemia

Francesco Buccisano, MD, University Tor Vergata, Rome, Italy, outlines the use of minimal residual disease (MRD) measurement in acute myeloid leukemia and outlines the use of MRD negativity in complete remission. Dr Buccisano also discusses assays to measure MRD, including next-generation sequencing and flow cytometry as well as the importance of improving the sensitivity of MRD assays. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Francesco Buccisano

Incorporating MRD assessment into clinical decision-making in AML: recent ELN guideline update
2:19
Incorporating MRD assessment into clinical decision-making in AML: recent ELN guideline update
Francesco Buccisano • 23 Mar 2026
The EBMT recommendations for MRD-guided interventions in patients with AML undergoing alloSCT
1:42
The EBMT recommendations for MRD-guided interventions in patients with AML undergoing alloSCT
Francesco Buccisano • 23 Mar 2026
Revisiting the WHO and ICC 2022 scores for AML and MDS: addressing differences between the systems
2:08
Revisiting the WHO and ICC 2022 scores for AML and MDS: addressing differences between the systems
Francesco Buccisano • 23 Mar 2026
Adapting MRD monitoring to each patient with AML based on their disease profile
1:32
Adapting MRD monitoring to each patient with AML based on their disease profile
Francesco Buccisano • 31 Mar 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals